Blockade of CD40 ligand suppresses chronic experimental myasthenia gravis by down-regulation of Th1 differentiation and up-regulation of CTLA-4.

@article{Im2001BlockadeOC,
  title={Blockade of CD40 ligand suppresses chronic experimental myasthenia gravis by down-regulation of Th1 differentiation and up-regulation of CTLA-4.},
  author={Sin Hyeog Im and Dora Barchan and Prasanta Kumar Maiti and Sara Fuchs and Miriam C. Souroujon},
  journal={Journal of immunology},
  year={2001},
  volume={166 11},
  pages={6893-8}
}
Myasthenia gravis (MG) and experimental autoimmune MG (EAMG) are T cell-dependent Ab-mediated autoimmune disorders, in which the nicotinic acetylcholine receptor (AChR) is the major autoantigen. Th1-type cells and costimulatory factors such as CD40 ligand (CD40L) contribute to disease pathogenesis by producing proinflammatory cytokines and by activating autoreactive B cells. In this study we demonstrate the capacity of CD40L blockade to modulate EAMG, and analyze the mechanism underlying this… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 32 extracted citations

Controlled release strategies for modulating immune responses to promote tissue regeneration.

Journal of controlled release : official journal of the Controlled Release Society • 2015
View 5 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…